Kalaris Therapeutics (NASDAQ:KLRS) Lowered to “Sell” Rating by Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other equities research analysts have also commented on KLRS. Weiss Ratings restated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. Chardan Capital initiated coverage on shares of Kalaris Therapeutics in a research note on Tuesday, December 23rd. They set a “buy” rating and a $19.00 price objective on the stock. Finally, Citigroup reissued an “outperform” rating on shares of Kalaris Therapeutics in a report on Thursday, December 18th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

Kalaris Therapeutics Price Performance

NASDAQ:KLRS opened at $9.82 on Friday. Kalaris Therapeutics has a 1-year low of $2.14 and a 1-year high of $12.90. The company has a 50-day moving average of $9.36 and a 200 day moving average of $6.91. The firm has a market cap of $183.63 million, a PE ratio of -2.60 and a beta of -0.13.

Insider Activity

In other news, Director Srinivas Akkaraju acquired 479,847 shares of Kalaris Therapeutics stock in a transaction dated Thursday, December 18th. The stock was purchased at an average cost of $10.42 per share, for a total transaction of $5,000,005.74. Following the completion of the purchase, the director directly owned 1,979,847 shares in the company, valued at $20,630,005.74. This trade represents a 31.99% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 74.99% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Kalaris Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. RTW Investments LP acquired a new position in Kalaris Therapeutics in the 4th quarter worth approximately $10,972,000. Paradigm Biocapital Advisors LP acquired a new stake in Kalaris Therapeutics during the 4th quarter valued at approximately $5,908,000. Siren L.L.C. lifted its stake in Kalaris Therapeutics by 36.9% during the 4th quarter. Siren L.L.C. now owns 435,798 shares of the company’s stock valued at $3,678,000 after acquiring an additional 117,534 shares during the period. Alyeska Investment Group L.P. purchased a new stake in shares of Kalaris Therapeutics in the 4th quarter valued at $3,402,000. Finally, Ikarian Capital LLC purchased a new stake in shares of Kalaris Therapeutics in the 4th quarter valued at $3,038,000. Institutional investors and hedge funds own 66.05% of the company’s stock.

Kalaris Therapeutics Company Profile

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.